Navigation Links
Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
Date:12/5/2012

BALTIMORE, Dec. 5, 2012 /PRNewswire/ -- Cerecor Inc today announced that it has signed an option with Johns Hopkins University (JHU) for an exclusive license to develop and commercialize small molecule D-Amino Acid Oxidase inhibitors ("DAAO inhibitors") that were developed at the Johns Hopkins Brain Science Institute ("BSi").

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

DAAO inhibitors inhibit the degradation of D-serine, an amino acid which has a central role in the normal function of the glutamate / NMDA system in the human brain.  Growing evidence suggests that deficits in glutamate transmission are central to the neurobiology of schizophrenia.  D-serine, when administered in multi-gram quantities per day, has been shown in multiple studies to improve cognition (executive function) and reduce positive symptoms in schizophrenics. DAAO inhibition in the brain, as a means of increasing D-serine levels, has been a target for treating schizophrenia by major pharmaceutical companies for many years. 

"This approach to improving glutamate transmission is to administer DAAO inhibitors systemically along with small, supplemental doses of D-serine, in a simple and elegant fashion analogous to the use of Sinemet® for the treatment of Parkinson's Disease, as originally conceptualized by Drs. Solomon Snyder and Barbara Slusher," said Dr. Blake Paterson, co-founder and CEO of Cerecor. "The licensing of the DAAO inhibitor platform will be an important milestone in the development of a novel therapeutic for schizophrenic patients, for whom persistent cognition dysfunction is widely recognized as an important gap in current therapeutic approaches."

Under the terms of the agreement with JHU, Cerecor will fund final lead selection efforts already underway at the BSi via a sponsored research agreement. Under the terms of the agreement, once BSi attains pre-specified lead candidate selection criteria, Cerecor plans to sign an exclusive, world-wide license agreement and assume development of the lead DAAO inhibitor candidate(s). JHU will receive an initial license fee and additional payments based upon achievement of specified development and commercialization milestones as well as royalties on net sales.

In 2013, Cerecor intends to complete the technology transfer activities and further examine the development and clinical profile of the lead candidate(s). This strategic evaluation will further inform potential implications for an early development clinical program.

About Cerecor:  Cerecor Inc is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and co-founded in April 2011 by Drs. Solomon Snyder, Barbara Slusher, Blake Paterson and Mr. Isaac Blech. Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

CONTACT: Karen Krumeich, +1-410-522-8707


'/>"/>
SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Magnus Persson Joins Cerecors Board of Directors
2. Cerecor Announces Initiation of CLIN01-002-A
3. Savient Announces the Election of Robert G. Savage to its Board of Directors
4. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
5. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
6. Tria Beauty, Inc. Announces Partnership with Jenny McCarthy
7. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
8. UBM Canon Announces its New Medical Technology Seminar Series
9. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
10. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
11. Ultra Clean Announces Participation in the Midtown CAP Summit Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... , ... June 28, 2017 , ... David B. Sosin, a founding partner ... took over the post of 2nd Vice President for the Illinois State Bar Association ... as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces ... of the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer ... as a regional supplier of garden pea seed. As demand grew, the small company ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
Breaking Medicine News(10 mins):